Sarepta Therapeutics Inc (SRPT)

141.53 +3.88 (+2.82%)
Close USD Disclaimer
142.50 +0.97 (+0.69%)

Sarepta Therapeutics Inc Company Profile

Sector
Healthcare
Employees
840
Equity Type
ORD
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It develops therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It commercializes three products, such as EXONDYS 51 (eteplirsen) Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53) and AMONDYS 45 (casimersen) Injection (AMONDYS 45). These commercial products are indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51, exon 53 and exon 45 skipping. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.
Contact Information
Address
Cambridge,02142 United States
Phone
617 274 4000
Fax
-
Top Executives
Name
Age
Since
Title
Douglas S. Ingram 58 2017 President, CEO & Director
M. Kathleen Behrens 69 2009 Independent Chairwoman
Beverly L. Davidson 0 2015 Member of Strategic & Scientific Advisory Board
Hans Wigzell 83 2010 Chairman of Corporate Strategy Board & Independent Non-Employee Director
Louis M. Kunkel 0 2015 Member of Strategic & Scientific Advisory Board
Kenneth H. Fischbeck 0 2017 Member of Strategic & Scientific Advisory Board
Matthew Wood 0 2017 Member of Strategic & Scientific Advisory Board
Steven Gray 0 2019 Member of Scientific Advisory Board
Angela J. Russell 0 2020 Member of Scientific Advisory Board
Carsten Bonnemann 0 2019 Member of Scientific Advisory Board
Kay Davies 0 2019 Member of Scientific Advisory Board
Annemieke Aartsma-Rus 0 2019 Member of Scientific Advisory Board
Joy A. Cavagnaro 0 2019 Member of Scientific Advisory Board
Stephen L. Mayo 60 2021 Independent Director
Michael Chambers 48 2022 Independent Director
Kathryn J. Boor 64 2022 Independent Director
Claude Nicaise 70 2015 Independent Non-Employee Director
Richard Jon Barry 64 2015 Independent Director
Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles